Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 2/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | PLTP | P55058 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
| ▸ | TUBB | P07437 | 1/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034276 | 1.00 | POLB (0.43) | POLBABCG2MEN1KMT2AMAPT | |
| SCHEMBL30549354 | 0.91 | SLC29A1 (0.43) | POLBABCG2TYMPSLC29A1 | |
| SCHEMBL21828804 | 0.91 | SLC29A1 (0.43) | POLBABCG2TYMPSLC29A1 | |
| SCHEMBL29674473 | 0.91 | SLC29A1 (0.43) | POLBABCG2TYMPSLC29A1 | |
| SCHEMBL22034033 | 0.84 | TYMP (0.47) | TYMPRETKDR | |
| SCHEMBL18490419 | 0.84 | TYMP (0.47) | TYMPRETKDR | |
| SCHEMBL27216186 | 0.84 | TYMP (0.47) | TYMPRETKDR | |
| SCHEMBL21577261 | 0.84 | TYMP (0.46) | POLBTYMP | |
| SCHEMBL532593 | 0.78 | TYMP (0.46) | POLBTYMP | |
| SCHEMBL18490599 | 0.78 | TYMP (0.38) | MAPTTYMPRETKDRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3891164-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117625-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | POLB 317/4885ABCG2 2436/4885MEN1 1602/4885 |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | POLB 332/4885ABCG2 2494/4885MEN1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.